The Government of Khyber Pakhtunkhwa has cleared the inherited liabilities to the tone of Rs78.5 billion and increased the ...

CSL Behring has shared positive four-year results from a late-stage study of its haemophilia B gene therapy Hemgenix ...

I am seeing patients stopping their medication or requesting vitamin drips after hearing about them from health and wellness influencers ...

Despite this, campaigning victims continue to highlight the lack of progress and the slow speed of compensation being ...

Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at Guggenheim in a research report issued on Monday,Benzinga reports. Separately, ...

“CSL delivered a solid result for the first half of the 2025 financial year led by CSL Behring. Strong demand for many of our market-leading therapies has translated into sales growth, particularly in ...

Oxford Cannabinoid Technologies is shedding its old skin. Having delisted its stock last year, the biotech is rebranding as ...

After years of medical issues, columnist G Shellye Horowitz has acquired numerous assistive devices, which come in handy ...

Antibody therapy Mim8 was found to be safe and effective for controlling bleeds in children with hemophilia A in a Phase 3 ...

Pfizer terminated partnership with Sangamo on hemophilia A gene therapy despite positive Phase 3 data. Find out why SGMO ...

Csl Ltd ( ($CSLLY) ) has released its Q2 earnings. Here is a breakdown of the information Csl Ltd presented to its investors.